Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M23,363Revenue (TTM) $M20,835Net Margin (%)-48.0Altman Z-Score--
Enterprise Value $M56,929EPS (TTM) $-10.1Operating Margin %17.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-58.0Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %--Quick Ratio0.7Cash flow > EarningsY
Price/Sales1.25-y EBITDA Growth Rate %--Current Ratio1.0Lower Leverage y-yY
Price/Free Cash Flow5.7y-y EBITDA Growth Rate %--ROA % (ttm)-13.2Higher Current Ratio y-yY
Dividend Yield %0.7PEG--ROE % (ttm)-46.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M1,018ROIC % (ttm)5.5Gross Margin Increase y-yN

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

TEVA is held by these investors:

TEVA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Codner Iris BeckEVP Global Brand&Communication 2018-08-09Sell4,165$22.76.7view
Dethlefs SvenEVP Global Marketing&Portfolio 2018-08-03Buy2,000$21.9210.49view
MIGNONE ROBERTODirector 2018-05-10Buy750,000$19.2425.88view
Stark David MatthewExec. VP Chief Legal Officer 2018-03-19Sell2,358$18.3831.77view
O'Grady Brendan P.EVP, North America Commercial 2018-03-19Sell1,179$17.8835.46view
Nazzi GianfrancoEVP, Growth Markets Commercial 2018-03-19Sell457$17.8935.38view
McClellan Michael JamesEVP, CFO 2018-03-19Sell287$17.8835.46view
Griffin Deborah AChief Accounting Officer 2018-03-19Sell943$17.8835.46view
Fridriksdottir HafrunExecutive VP, Global R&D 2018-03-19Sell348$17.8835.46view
Dethlefs SvenEVP Global Marketing&Portfolio 2018-03-19Sell571$17.8835.46view

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain Aug 16 2018 
    US Stock Market Opens Lower on Thursday Aug 02 2018 
    Bernard Horn Comments on Teva Pharmaceuticals Jul 23 2018 
    Bernard Horn's Polaris Global Value Fund 2nd Quarter Letter Jul 23 2018 
    Analysis: Positioning to Benefit within Teva Pharmaceutical Industries, Resonant, United Community F Jun 07 2018 
    3 Stocks Move Wednesday May 16 2018 
    Warren Buffett Boosts 6 Positions in 1st Quarter May 15 2018 
    David Abrams' Top Buys and Sells in 1st Quarter May 14 2018 
    2 Stocks to Watch on Thursday May 03 2018 
    Procter & Gamble Down Despite Earnings Beat Apr 24 2018 

    More From Our Partners
    Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic Aug 17 2018 - ZACKS
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat